Home | Newsletters|
Bookstore | News | Community
| Links | Articles/FAQs | Diet Info Ctr | Top Drs | Contact
New Therapies for Autoimmune Diseases
|
December 2003 -- GMP Immunotherapeutics, Inc., in conjunction with the University of Michigan, will develop a novel class of molecules designed to treat systemic lupus erythematosus (lupus), rheumatoid arthritis, psoriasis and some forms of cancer. This involves application of novel benzodiazepine derivatives against a new molecular target. In the treatment of an autoimmune disease like lupus, cytotoxicity is an important mechanism. A class of cytotoxic benzodiazepines has been found to alter the progression of autoimmune diseases like lupus and rheumatoid arthritis by selectively inducing apoptosis (cell death) of the immune cells that mediate these disease processes. The best currently available drugs do are not effective in some patients with lupus while in others the side effects cause discontinuation of treatment. It is hoped that this new approach will yield drugs that will be more selective thus offering greater effectiveness with minimal side effects. Source: PRNewswire FOR MORE INFORMATION  For more information on multiple sclerosis and other autoimmune diseases, read my book, Living Well With Autoimmune Disease.
| |||||||||
|
All information is intended for your general knowledge only and is not a substitute for medical advice or treatment for specific medical conditions. You should seek prompt medical care for any specific health issues and consult your physician or health practitioner before starting a new treatment program. Please see our full disclaimer. | ||||||||||